Literature DB >> 26488675

Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics.

Tzung-Jeng Hwang1, Wei-Ming Lo, Hung-Yu Chan, Ching-Feng Lin, Ming H Hsieh, Chen-Chun Liu, Chih-Min Liu, Hai-Gwo Hwu, Ching-Hua Kuo, Wei J Chen.   

Abstract

This study aimed to compare strategies differing in the speed of switching schizophrenic patients to aripiprazole from other antipsychotic agents, with dual administration for 2 weeks and then tapering off the current antipsychotic in fast (within 1 week) versus slow (within 4 weeks) strategies. This 8-week, open-label, randomized, parallel study assigned patients with a primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of schizophrenia or schizoaffective disorder to either the fast-switching (n = 38) or slow-switching (n = 41) group. Efficacy assessments at 5 time points included Positive and Negative Syndrome Scale and Clinical Global Impression scale. Safety assessments included extrapyramidal symptoms, metabolic profile, serum prolactin level, QTc interval, and adverse events. Drug concentrations and cytochrome P450 CYP2D6 and CYP3A4 genotypes were also measured. The fast- and slow-switching groups were comparable in demographical and clinical features at baseline and dropout rate. In the intention-to-treat analysis using mixed-effects models, there were significant within-group decreases over time in the Positive and Negative Syndrome Scale total scores (P = 0.03) and its subscores except for positive subscores, whereas no between-group differences were found. A reduction in body weight (P = 0.01) and lower levels of total cholesterol (P = 0.03), triglycerides (P = 0.03), and prolactin (P = 0.01) were noted in both groups but no increase in extrapyramidal symptoms or prolongation of QTc. The blood concentrations of aripiprazole in all patients were in a therapeutic range at day 56, with CYP2D6*10 polymorphisms being associated with aripiprazole concentrations. In conclusion, there is no significant difference between the fast- and slow-switching strategy in terms of improvements in clinical symptoms and metabolic profile in this 8-week study.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26488675     DOI: 10.1097/JCP.0000000000000426

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  10 in total

Review 1.  Antipsychotic combinations for schizophrenia.

Authors:  Javier Ortiz-Orendain; Santiago Castiello-de Obeso; Luis Enrique Colunga-Lozano; Yue Hu; Nicola Maayan; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2017-06-28

Review 2.  Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis.

Authors:  Xenia M Hart; Christoph Hiemke; Luzie Eichentopf; Xenija M Lense; Hans Willi Clement; Andreas Conca; Frank Faltraco; Vincenzo Florio; Jessica Grüner; Ursula Havemann-Reinecke; Espen Molden; Michael Paulzen; Georgios Schoretsanitis; Thomas G Riemer; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2022-10-05       Impact factor: 4.415

3.  Pharmacological treatment strategies for antipsychotic-induced hyperprolactinemia: a systematic review and network meta-analysis.

Authors:  Zhe Lu; Yaoyao Sun; Yuyanan Zhang; Yu Chen; Liangkun Guo; Yundan Liao; Zhewei Kang; Xiaoyang Feng; Weihua Yue
Journal:  Transl Psychiatry       Date:  2022-07-05       Impact factor: 7.989

4.  Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole.

Authors:  Yoshiaki Obayashi; Satoshi Mitsui; Shinji Sakamoto; Nozomu Minao; Bunta Yoshimura; Toshiki Kono; Yuji Yada; Yuko Okahisa; Soshi Takao; Yoshiki Kishi; Toshihiko Takeda; Manabu Takaki; Norihito Yamada
Journal:  Psychopharmacology (Berl)       Date:  2019-10-18       Impact factor: 4.530

5.  Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis.

Authors:  Dan Siskind; Erin Gallagher; Karl Winckel; Samantha Hollingworth; Steve Kisely; Joseph Firth; Christoph U Correll; Wade Marteene
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

Review 6.  TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel.

Authors:  Baybars Veznedaroglu; Nesrin Dilbaz; Ozcan Uzun; Erdal Isik
Journal:  Ther Adv Psychopharmacol       Date:  2018-05-04

7.  Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms?

Authors:  Ya-Wen Jen; Tzung-Jeng Hwang; Hung-Yu Chan; Ming H Hsieh; Chen-Chung Liu; Chih-Min Liu; Hai-Gwo Hwu; Ching-Hua Kuo; Yi-Ting Lin; Yi-Ling Chien; Wei J Chen
Journal:  BMC Psychiatry       Date:  2020-11-23       Impact factor: 3.630

8.  Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis.

Authors:  Helene Speyer; Casper Westergaard; Nikolai Albert; Mette Karlsen; Anne Emilie Stürup; Merete Nordentoft; Jesper Krogh
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-28       Impact factor: 5.555

Review 9.  Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.

Authors:  Nobuhisa Kanahara; Hiroshi Kimura; Yasunori Oda; Fumiaki Ito; Masaomi Iyo
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

10.  Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia.

Authors:  Chia-Hao Ma; Hung-Yu Chan; Ming H Hsieh; Chen-Chung Liu; Chih-Min Liu; Hai-Gwo Hwu; Ching-Hua Kuo; Wei J Chen; Tzung-Jeng Hwang
Journal:  Ther Adv Psychopharmacol       Date:  2022-01-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.